Q1 2026 report
genXone to spółka biotechnologiczna z NewConnect działająca w sekwencjonowaniu nanoporowym i diagnostyce molekularnej — mała skala przychodów (491 tys. zł w I kw. 2026), ale wyraźnie poprawiająca się dynamika.
Sentiment
Positive
No guidance change
GX1
Q1 2026 report
Revenue
0.49 m PLN
— YoY
Net income
-0.52 m PLN
— YoY
EBITDA
-0.36 m PLN
— YoY
FCF
-0.32 m PLN
— YoY
Summary
Investment thesis
- Przychody wzrosły o 15% r/r (490,9 tys. zł vs 427,1 tys. zł), a strata netto zawęziła się o 215,4 tys. zł r/r (do -517 tys. zł) — druga z rzędu poprawa wyniku r/r, po podobnej poprawie w IV kw. 2025 r.
- OCF wciąż ujemny (-323,3 tys. zł), ale wyraźnie mniejszy niż rok wcześniej (-726,3 tys. zł) — tempo spalania gotówki spadło niemal o połowę.
- W marcu 2026 r. spółka podpisała umowę z Narodowym Instytutem Geriatrii, Reumatologii i Rehabilitacji na sekwencjonowanie mikrobiomu o wartości 246,7 tys. zł z terminem realizacji do 31.07.2027 r. — konkretny, potwierdzony przychód na kolejne kwartały.
- Gotówka na koniec kwartału to 3,06 mln zł — przy obecnym tempie spalania gotówki (ok. 323 tys. zł/kwartał) daje to płynnościowy bufor rzędu ~9 kwartałów, o ile tempo nie przyspieszy.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
GX1 · Q1 2026
| Metric | Q1 2026 | Q1 2025 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|
| Revenue | 0.49 | — | — | reported | — | 1.00 |
| EBITDA | -0.36 | — | — | reported | — | 0.90 |
| EBIT | -0.54 | — | — | reported | — | 1.00 |
| EBT | -0.51 | — | — | reported | — | 1.00 |
| Net income | -0.52 | — | — | reported | — | 1.00 |
| EPS (basic) (PLN) | -0.16 | — | — | derived | — | 0.60 |
| D&A | 0.18 | — | — | reported | — | 1.00 |
| Interest expense | 0 | — | — | reported | — | 1.00 |
| Shares (basic) (m units) | 3.3 | — | — | reported | — | 0.90 |
| EBITDA margin | -73.38% | — | — | reported | — | 0.90 |
| EBIT margin | -109.78% | — | — | reported | — | 1.00 |
| EBT margin | -104.5% | — | — | reported | — | 1.00 |
| Net margin | -105.31% | — | — | reported | — | 1.00 |
| Cash | 3.06 | — | — | reported | — | 1.00 |
| Equity | 7.89 | — | — | reported | — | 1.00 |
| Total assets | 8.34 | — | — | reported | — | 1.00 |
| Working capital | 3.33 | — | — | reported | — | 1.00 |
| Current assets | 3.69 | — | — | reported | — | 1.00 |
| Current liabilities | 0.36 | — | — | reported | — | 1.00 |
| Goodwill | 4.41 | — | — | reported | — | 1.00 |
| Tangible equity | 3.49 | — | — | reported | — | 0.90 |
| CFO | -0.32 | — | — | reported | — | 1.00 |
| CapEx | 0 | — | — | reported | — | 1.00 |
| FCF | -0.32 | — | — | reported | — | 1.00 |
| Current ratio | 10.16x | — | — | reported | — | 1.00 |
| Quick ratio | 9.61x | — | — | reported | — | 0.90 |
| Cash ratio | 8.41x | — | — | reported | — | 1.00 |
| Revenue growth (YoY) | 14.96% | — | — | reported | — | 1.00 |
| EBITDA growth (YoY) | 27.69% | — | — | reported | — | 0.80 |
| EBIT growth (YoY) | 31.42% | — | — | reported | — | 0.80 |
| Net income growth (YoY) | 29.41% | — | — | reported | — | 0.80 |
| EPS growth (YoY) | 29.41% | — | — | reported | — | 0.60 |
| EBIT margin Δ (YoY) | 74.23 pp | — | — | reported | — | 0.90 |
| Net margin Δ (YoY) | 66.17 pp | — | — | reported | — | 0.90 |
Q1 2026 · Δ YoY
Revenue
0.49
—
0.49
—
- Q1 2025
- —
EBITDA
-0.36
—
-0.36
—
- Q1 2025
- —
EBIT
-0.54
—
-0.54
—
- Q1 2025
- —
EBT
-0.51
—
-0.51
—
- Q1 2025
- —
Net income
-0.52
—
-0.52
—
- Q1 2025
- —
EPS (basic)
(PLN)
-0.16
—
-0.16
—
- Q1 2025
- —
D&A
0.18
—
0.18
—
- Q1 2025
- —
Interest expense
0
—
0
—
- Q1 2025
- —
Shares (basic)
(m units)
3.3
—
3.3
—
- Q1 2025
- —
EBITDA margin
-73.38%
—
-73.38%
—
- Q1 2025
- —
EBIT margin
-109.78%
—
-109.78%
—
- Q1 2025
- —
EBT margin
-104.5%
—
-104.5%
—
- Q1 2025
- —
Net margin
-105.31%
—
-105.31%
—
- Q1 2025
- —
Cash
3.06
—
3.06
—
- Q1 2025
- —
Equity
7.89
—
7.89
—
- Q1 2025
- —
Total assets
8.34
—
8.34
—
- Q1 2025
- —
Working capital
3.33
—
3.33
—
- Q1 2025
- —
Current assets
3.69
—
3.69
—
- Q1 2025
- —
Current liabilities
0.36
—
0.36
—
- Q1 2025
- —
Goodwill
4.41
—
4.41
—
- Q1 2025
- —
Tangible equity
3.49
—
3.49
—
- Q1 2025
- —
CFO
-0.32
—
-0.32
—
- Q1 2025
- —
CapEx
0
—
0
—
- Q1 2025
- —
FCF
-0.32
—
-0.32
—
- Q1 2025
- —
Current ratio
10.16x
—
10.16x
—
- Q1 2025
- —
Quick ratio
9.61x
—
9.61x
—
- Q1 2025
- —
Cash ratio
8.41x
—
8.41x
—
- Q1 2025
- —
Revenue growth (YoY)
14.96%
—
14.96%
—
- Q1 2025
- —
EBITDA growth (YoY)
27.69%
—
27.69%
—
- Q1 2025
- —
EBIT growth (YoY)
31.42%
—
31.42%
—
- Q1 2025
- —
Net income growth (YoY)
29.41%
—
29.41%
—
- Q1 2025
- —
EPS growth (YoY)
29.41%
—
29.41%
—
- Q1 2025
- —
EBIT margin Δ (YoY)
74.23 pp
—
74.23 pp
—
- Q1 2025
- —
Net margin Δ (YoY)
66.17 pp
—
66.17 pp
—
- Q1 2025
- —